ONCO
$0.52
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union.
Recent News
Realbotix Announces the Sale of Realbotix, LLC Subsidiary to Onconetix
Realbotix (XBOT.V) on Thursday said it entered into a definitive agreement with Onconetix, Inc (NASD
Onconetix announces financing through private placement, debt settlement
Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shares of the Company’s common stock, $0.00001 par value per share, for an aggregate purchase price of approximately $12.9 million. Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investo
Onconetix receives additional delisting notice from Nasdaq
Onconetix (ONCO) received a staff delisting letter from Nasdaq on May 20 indicating that the company’s failure to file its Quarterly Report Q for the three months ended March 31, 2025 is in violation of Nasdaq’s continued listing requirements. The company received a deficiency notice from Nasdaq that the company was not in compliance with Nasdaq’s Listing Rules as set forth in the Rule given the company’s failure to timely file its Annual Report on Form 10-K for FY24. The company received a Staf
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort
The company states: “Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European Association of Urology congress, which data further demonstrates the strong clinical performance of Proclarix in a Danish cohort. The primary approach for early detection of prostate cancer is through testing serum levels of prostate-specific antigen, or PSA. However, given the limited cancer specificity of PSA, Proclarix(R) is addressing the urgent need fo